Ning et al. developed dual targeting conjugates by joining Res and oxabicycloheptene sulfonate (OBHS), a structural motif of estrogen receptor (ER), with the aim of suppressing estrogenic and anti-inflammatory activities in breast cancer cells (MCF-7) [52]. Here, ESR1 is linked to breast cancer.